Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Nissen

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
American Heart Journal|August 10, 2016
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes TrialsPaul M Ridker, Pierre Amarenco, Robert Brunell, et al.
Journal of the American College of Cardiology|January 28, 2012
Highlights of the Year in JACC 2011Anthony N Demaria, Jeroen J Bax, Ori Ben-Yehuda, et al.
Journal of the American College of Cardiology|February 2, 2010
Highlights of the Year in JACC 2009Anthony N DeMaria, Jeroen J Bax, Ori Ben-Yehuda, et al.
Journal of the American College of Cardiology|January 22, 2011
Highlights of the year in JACC 2010Anthony N DeMaria, Jeroen J Bax, Ori Ben-Yehuda, et al.
The New England Journal of Medicine|March 18, 2017
Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabPaul M Ridker, Jean-Claude Tardif, Pierre Amarenco, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|December 13, 2024
Upstream targeting for the prevention of atrial fibrillation: Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)-rationale and study designSojin Y Wass, John Barnard, Hyun Su Kim, et al.
The New England Journal of Medicine|March 18, 2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsPaul M Ridker, James Revkin, Pierre Amarenco, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
American Heart Journal|August 10, 2016
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes TrialsPaul M Ridker, Pierre Amarenco, Robert Brunell, et al.
Journal of the American College of Cardiology|January 28, 2012
Highlights of the Year in JACC 2011Anthony N Demaria, Jeroen J Bax, Ori Ben-Yehuda, et al.
Journal of the American College of Cardiology|February 2, 2010
Highlights of the Year in JACC 2009Anthony N DeMaria, Jeroen J Bax, Ori Ben-Yehuda, et al.
Journal of the American College of Cardiology|January 22, 2011
Highlights of the year in JACC 2010Anthony N DeMaria, Jeroen J Bax, Ori Ben-Yehuda, et al.
The New England Journal of Medicine|March 18, 2017
Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabPaul M Ridker, Jean-Claude Tardif, Pierre Amarenco, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|December 13, 2024
Upstream targeting for the prevention of atrial fibrillation: Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)-rationale and study designSojin Y Wass, John Barnard, Hyun Su Kim, et al.
The New England Journal of Medicine|March 18, 2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsPaul M Ridker, James Revkin, Pierre Amarenco, et al.
Pageof 4